Treatment of tardive dyskinesia with dihydrogenated ergot alkaloids (hydergine): a pilot study.
Five patients with abnormal involuntary movements of tardive dyskinesia were treated with dihydrogenated ergot alkaloids (Hydergine) in doses of 3 to 4 milligrams a day for six weeks. Blind ratings of standard videotape recordings indicated significant differences between the patients. Worsening occurred in three patients during treatment and to a lesser extent after treatment; improvement during treatment appeared in one patient and more sustained improvement in one patient.
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents; D004088:Dihydroergotoxine